Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Brief Summary: RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether androgen-ablation therapy is more effective with or without docetaxel in treating metastatic prostate cancer.

PURPOSE: This randomized phase III trial is studying androgen-ablation therapy and chemotherapy to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.


Options:
A: Arm Label: Mitoxantrone + Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: mitoxantrone, Drug: prednisone | Arm Label: Cabazitaxel + Prednisone; Type: EXPERIMENTAL; Interventions: Drug: cabazitaxel (XRP6258) (RPR116258), Drug: prednisone | Intervention Type: DRUG; Name: cabazitaxel (XRP6258) (RPR116258); Assigned to Arm(s): Cabazitaxel + Prednisone | Intervention Type: DRUG; Name: mitoxantrone; Assigned to Arm(s): Mitoxantrone + Prednisone | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Cabazitaxel + Prednisone, Mitoxantrone + Prednisone
B: Arm Label: Androgen-Deprivation Therapy and Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: androgen-deprivation therapy, Drug: docetaxel | Arm Label: Androgen-Deprivation Therapy alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: androgen-deprivation therapy | Intervention Type: DRUG; Name: androgen-deprivation therapy; Assigned to Arm(s): Androgen-Deprivation Therapy alone, Androgen-Deprivation Therapy and Docetaxel | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Androgen-Deprivation Therapy and Docetaxel
C: Arm Label: Enzalutamide; Type: EXPERIMENTAL; Interventions: Drug: Enzalutamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Enzalutamide; Assigned to Arm(s): Enzalutamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Abiraterone acetate + Prednisone + ADT; Type: EXPERIMENTAL; Interventions: Drug: Abiraterone acetate, Drug: Prednisone, Other: Androgen deprivation therapy (ADT) | Arm Label: Placebo + Androgen Deprivation Therapy (ADT); Type: PLACEBO_COMPARATOR; Interventions: Other: Androgen deprivation therapy (ADT), Drug: Abiraterone acetate Placebo, Drug: Prednisone Placebo | Intervention Type: DRUG; Name: Abiraterone acetate; Assigned to Arm(s): Abiraterone acetate + Prednisone + ADT | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Abiraterone acetate + Prednisone + ADT | Intervention Type: OTHER; Name: Androgen deprivation therapy (ADT); Assigned to Arm(s): Abiraterone acetate + Prednisone + ADT, Placebo + Androgen Deprivation Therapy (ADT) | Intervention Type: DRUG; Name: Abiraterone acetate Placebo; Assigned to Arm(s): Placebo + Androgen Deprivation Therapy (ADT) | Intervention Type: DRUG; Name: Prednisone Placebo; Assigned to Arm(s): Placebo + Androgen Deprivation Therapy (ADT)

Answer: B